TrialInternational journal of clinical oncology2022

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).

Yukari Tsubata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.